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Abstract
Background: The concept of health-related quality of life (HRQoL) was brought up decades ago and has been well
utilized in many different areas. Regarding immune thrombocytopenia (ITP) management, much work has been
done to emphasize the necessity of taking HRQoL into consideration. However, data on HRQoL of children with
chronic ITP remain rare.
Methods: This is a cross-sectional study. Children with chronic ITP aged from 2 to 18 and their parents were
recruited. Participants completed the Pediatric Quality of Life Inventory™ (PedsQL™) and Kids’ ITP Tools (KIT)
questionnaires at only one time. The Pearson’s correlation was examined between these measures for the
pooled samples.
Results: A total of 42 families participated. Mean child self-report scores of KIT and PedsQL™ were 78.60 (SD = 12.40)
and 85.13 (SD = 14.12), respectively, corresponding to parent proxy report scores, which were 73.40 (SD = 19.96) and
85.10 (SD = 13.56), respectively. Mean score of KIT parent impact report was only 40.39 (SD = 19.96). Significantly
higher KIT scores (self-report and parent proxy) were observed in children with PLT more than 30 × 10*9/L
compared to others, and this difference was even more noticeable in the PedsQL™ parent proxy report group
(p < 0.001). As with intravenous immunoglobulin, the statistics difference appeared only in KIT child self-report
group (p = 0.03), while for bone marrow examination, the difference appeared only in PedsQL™ parent proxy
report group (p = 0.01). A negative relationship was apparent between duration of disease and scores. Gender
and use of corticosteroids had no impact on the KIT and PedsQL™ scores here. Internal consistency reliability
was demonstrated with Cronbach’s alpha for all scales above the acceptable level of 0.89 (range from 0.88 to
0.97). There was a substantial concordance (p < 0.001) between the child and parent proxy scores (ICC for KIT is
0.59, ICC for PedsQL™ is 0.85). Meanwhile, KIT scores are correlated with PedsQL™ (r = 0.75 for child self report,
r = 0.61 for parent proxy report).
Conclusions: ITP affects HRQoL of children and parents. Parents are much more concerned with the disease
than their children, which seriously influence their HRQoL as a result. The cross-culture translated KIT is reliable
and valid with acceptable correlation to the PedsQL™. KIT provides valuable information of childhood ITP and
will be a reliable outcome measure for further clinical research on HRQoL.
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Background
Immune thrombocytopenia (ITP), characterized by
acquired decrease in peripheral blood platelets and
suppression of platelet production, is associated with
some symptoms such as spontaneous bruising, mucosal
bleeding, epistaxis, or to severe even fatal bleeding events
and intracranial hemorrhage [1, 2]. Based on current esti-
mation, the prevalence of ITP in children is about 4–6
cases per 100,000 annually [3]. Approximately, 20–25 %
children with ITP become chronic (defined as peripheral
blood platelet count <100 × 10*9/L and lasting for over
12 months) [4–9]. Recent reports show that for those
diagnosed as chronic ITP, around 50 % children spontan-
eously recover within 5 years and a few may take more
years [6]. ITP children’s families have to deal with incessant
worries of bleeding, fears of invasive procedures (like blood
tests, bone marrow aspiration and intravenous therapy) and
risk of splenectomy, which will obviously affects their qual-
ity of life [10, 11]. Moreover, restrictions on lifestyle and the
side effects of corticosteroid therapy, the most serious such
as avascular necrosis, could even worsen it [10].
Recent guidelines emphasize the necessity of taking
the issues on health related quality of life (HRQoL) into
consideration while making decisions on management in
childhood ITP, rather than just focusing on increasing
platelet counts [12]. Some researches also support
HRQoL to play a major role in treating patients with
chronic diseases, which attracts our attention to explore
the quality of life of childhood chronic ITP [13, 14].
HRQoL assessment provides a comprehensive vision of
the patients’ subject feeling of well-being and function
and, in the meantime, supports analyzing treatment
effects [14]. The Kids’ ITP Tools (KIT), developed by
Robert Klaassen and Barnard et al. from Canada, is a
well-known disease-specific measure of HRQoL for
childhood ITP patients and families [15, 16]. Till now, it
has been validated in several countries, including UK,
France, Germany, Uruguay and Egypt. However, China
has only a few research records on chronic ITP HRQoL,
which barely related to health improvement [17]. The
Pediatric Quality of Life Inventory™ (PedsQL™) is a gen-
eral measurement on HRQoL of children, which has
been widely used around the world [18–20]. Thusly, we
conduct a cross-section study to evaluate HRQoL in
Chinese childhood chronic ITP patients by using KIT
and PedsQL™. The objective of this prospective study is
to improve the understanding of these patients and their
families’ experience of life and advocate using QoL as
key factor when considering clinical treatment.
Methods
Patients
From December 2013 to January 2015, 42 subjects with
chronic ITP and their parents were recruited from the
Nanjing Children’s Hospital Affiliated Nanjing Medical
University and Children’s Hospital of Hebei Province.
Parents or legal guardians of the subjects were inter-
viewed in person to collect clinical information. The 42
subjects included 29 boys and 13 girls, with an median
age of 5.79 (SD = 2.867). The lower limit of 2 years was
used since the KIT was designed for children of 2 year-
old or above. In the absence of a gold-standard test for
ITP, the diagnosis of chronic ITP was based on isolated
thrombocytopenia (platelet count < 100 g/L lasting for
over 12 months) without any identified causes (normal
hemoglobin level and white cell count and no hepatos-
plenomegaly or lymphadenopathy or significant abnor-
malities on blood smear, and no other chronic illness).
Patients with secondary ITP associated with immune
deficiency, collagen vascular disorder, or other causes
were excluded. Children ≥7 years old were required to
complete self-report versions of the KIT and self-report
versions of the PedsQL™.
Measures
This is a cross-sectional study with the questionnaires
being completed by the participants at one time only.
The generic and disease-specific HRQoL questionnaires
were combined in the study. KIT is a disease-specific
HRQoL measure that was initially developed and vali-
dated in North America and subsequently developed for
use in other languages and cultures [15, 17]. KIT can be
used in both clinic and home settings [15]. The measure
consists of 3 questionnaires: one version for the child
aged from 7 to 18 (child self-report), one for the parent
to complete on behalf of the child aged from 2 to 18
(parent proxy report) and another for the parent to
complete (parent impact report) [16]. The children’s ver-
sion of the KIT consists of 25 items and parents’ version
consists of 26 items. They were divided into separate
domains as follows: children’s version: treatment side
effects, intervention-related, disease-related, activity-
related, and family-related concerns; parental version:
diagnosis-related, monitoring-related, child’s restricted
activity-related, daily life-related, disease outcome and
emotional impact [16]. Scores for the individual domains
are summed to yield a total KIT score. KIT scores have a
range of 0 (worst) to 100 (best). Children ≥7 years old
were asked to complete a self-report KIT, and parents
completed a proxy KIT for their children and self-report
for them.
PedsQL™ has undergone rigorous psychometric test-
ing, and also has child and parent report components
that are valid, reliable and responsive in the target
countries [18–20]. The Chinese version of PedsQL™ has
been in use regionally for at least 10 years and proven
well established [21, 22]. We used the young child
version (parent-assisted) for 5–7 years old, the child
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version (self-report) for 8–12 years old and the teen
version (self-report) for 13–18 years old, and the 2–5,
5–7, 8–12 years parent-report versions [19, 20]. Scores
for PedsQL™ also range from 0 (worst) to 100 (best).
The age-specific questionnaires were handed in hard
copy to parents and patients in clinic and were filled out
in the waiting room. Local investigators sent completed
questionnaires by mail to the coordinating investigator.
Data were entered in an electronic database by researchers
of the coordinating study center.
Data checks and cleaning were performed on all data.
All data were double entered to ensure accuracy. If 25 %
or more of the item data were missing, the summary
score would not be calculated.
Statistical analysis
Statistical analyses here were performed using Statistical
Package for Social Science (version 14.0; SPSS). Qualita-
tive variables were described in number and percentages
and mean ± SD, if quantitative. Internal consistency of
the Chinese version of the KIT was analyzed by measur-
ing Cronbach α test in the whole sample according to
different respondents. Independent sample test was used
to compare between means of different groups of pa-
tients. ANOVA tests were used when comparing quanti-
tative data between more than 2 groups. The Pearson
and Spearman coefficients were used when studying the
relationship (direction and power) of quantitative vari-
ables simultaneously. Linear regression analysis was used
to examine the extent to which a set of variables inde-
pendently predicts a dependent variable. Two-sided P




The frequency distributions of all subjects of the
selected variables are summarized in Table 1. The
median age was 5.79 years old along with median age at
diagnosis of ITP was 4.47 years old. Of the 42 chronic
ITP patients, 37 children underwent bone marrow
(BM) aspiration at diagnosis. The treatment protocol
varied and included oral and intravenous steroids, im-
munoglobulin, and splenectomy and platelet infusion.
Thirty-six children (85.7 %) received corticosteroids
treatment. Twenty-five (59.5 %) received intravenous
immunoglobulin (IVIG). Of all the patients, only one
child received splenectomy and none had received
platelet infusion. There are 16 patients with Platelet
count (PLT) lower than 30 × 10*9/L at the past week of
investigation. The diagnosis of chronic ITP is in
accordance with classification of the American Society
of Hematology 2011 evidence-based practice guideline
for immune thrombocytopenia [12].
PedsQL™ and KIT scores of children
The results of this comparison are shown in Table 2. All
patients had completed the parent version of the KIT
and PedsQL™ and for the child self-assessment version.
Twenty-four patients were old enough to complete it
independently.
The mean score for KIT child self-report was 78.60
(SD = 12.40), ranging from 55.21 to 98.68. For parent
proxy report and parent impact report measurement,
the scores were 73.40 (SD = 19.96, range from 17.31 to
100) and 40.39 (SD = 19.96, range from 6.73 to 81.73),
respectively. The PedsQL™ score was slightly higher with
child-report mean of 85.13 (SD = 14.12; range from
63.04 to 100) and parent proxy report mean of 85.10
(SD = 13.56; range from 55.68 to 100). There were no
significant differences between total scores of proxy
and child self-report in PedsQL™ or KIT (p = 0.527
and p = 0.095, respectively). But it was observed that
scores of children report were higher than those of
parent proxy report in KIT, the difference approached
but did not achieve statistical significance (p = 0.095)
which did not differ in PedsQL™.
Interval between intervention and KIT was within
4 weeks. No major relation was found between gender
and corticosteroids of the patients with either scores of
child/proxy reports or parent reports. But it was observed
that significantly higher KIT scores (self-report and parent
proxy) in children with PLT more than 30 × 10*9/L com-
pared to the group of PLT less than 30 × 10*9/L. This
difference was reinforced in the PedsQL™ Parent report
group (p < 0.001). As with intravenous immunoglobulin,
the statistics difference appeared only in KIT child self-
Table 1 Frequency distribution of selected variables in ITP
patients
Patients (n = 42)
Variables n %
Median age (years) 5.79











Platelet infusion 0 0
PLT Blood platelet, IVIG Intravenous immunoglobulin, BM Initial bone
marrow examination
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report group (p = 0.03), while for bone marrow examin-
ation, the difference appeared only in PedsQL™ parent
proxy report group (p = 0.01).
Table 4 describes the correlations between mean
scores and age at onset, as well as duration of disease
and platelet count. As expected, a negative or inverse
relation was apparent between duration of disease and
scores. This was statistically significant in KIT Parent
report Scores (r = −0.426, p = 0.005) and PedsQL™ child
self report scores (r = −0.461, p = 0.031). A significantly
positive correlation was found between platelet count
and scores of KIT Child self-report, PedsQL™ Child self-
report and PedsQL™ Parent report (r = 0.436, p = 0.033
and r = 0.531, p = 0.011 and r = 0.505 p = 0.001, respect-
ively). Age at onset did not seem to be correlated with
the KIT and PedsQL™ scores in patients.
Validation and reliability
The assessment of validity was based on the Pearson’s
correlation between the KIT and PedsQL™. The results
showed the correlation between the KIT and PedsQL™
scores was 0.75 for child self-report and 0.61 for parent
proxy report. All correlations were statistically signifi-
cant (p < 0.0001). Child self-report had the higher corre-
lations with parent proxy report in PedsQL™(r = 0.85)
and a lower one in KIT (r = 0.51). Internal consistency
reliability was demonstrated with Cronbach’s alpha for
all scales above the acceptable level of 0.89 (range:
0.89–0.97). As Table 2 shows, there was also a sub-
stantial concordance (p < 0.001) between the children’s
summary scores and the parent proxy report scores
for the two measures (ICC for KIT is 0.59, ICC for
PedsQL™ is 0.85).
Discussion
This is the first study to identify HRQoL of childhood
chronic ITP in China. We found that chronic ITP could
have adverse effects on children’ and their parents’ func-
tioning and well-beings, although some observations
indicated that newly diagnosed childhood ITP had a sig-
nificant impact on patients and their families [6]. Those
parents and children usually have impaired HRQoL, as a
result of the limitation of daily activity, disturbed sleep,
social and emotional functioning. Known as a self-
limiting disease, childhood ITP leads to a very low rate
of mortality and severe morbidity [10, 23]. But con-
fronted with chronic ITP, the physicians do not know
whether and when will the patients recover, which
brings endless anxiety to the patients and the families.
When faced with unpredictable bleeding events as well
as the adverse effects of treatment, children and the
families show more concerns, therefore affects the whole
families’ quality of life. To better fit the subject’s
perspectives and help develop a more efficient clinic
therapy, both KIT and PedsQL™ questionnaires were
used here to systemically analyze HRQoL in children
with chronic ITP. The study demonstrates that the KIT
remains valid and reliable and adaptable to Chinese
culture after translation into Chinese.
The median age of patients was 5.79 years old, while
the median age at diagnosis was 4.47 years old, which
agreed with the common stating that ITP most com-
monly occurred in children from 4 to 6 [12, 24]. Scores
of parent proxy report stay lower than child self-report
group of KIT, however, scores of PedsQL™ did not make
a difference. The reason for these findings could be that
the PedsQL™ only focus on the general parts such as the
ability to walk, run and so on, which may not be
restricted in most children, while KIT pays more atten-
tion to the disease-related function. This difference may
reflect parents’ concerns are more about disease-related
impact, while children adapt to their situation faster
than their parents. This discrepancy was comparable to
Zilber’s study, which has been proven a common finding
by lots of researches [25]. As Rama Zilber mentioned,
the basic concern of all parents was about the health
and future of their children, the life experiences and
inner life of children were different from adults, which
reflected their different priorities [25].
Many consensuses have reported that a BM aspirate
should be performed in children with newly diagnosed
ITP and atypical features [12, 26, 27]. Some researchers
believe that conducting a BM test become a major issue
bothering children. In this study, as with bone marrow
Table 2 Scores for child/proxy groups and reliability of KIT and PedsQL™
HRQoL Scales N Scores Reliability
Mean values (SD) MINI MAX Cronbach’s alpha ICC
KIT
Child self-report 24 78.60 (12.40) 55.21 98.68 0.88 0.59
Parent proxy report 42 73.40 (19.96) 17.31 100.00 0.97
PedsQL™
Child self-report 22 85.13 (14.12) 63.04 100 0.89 0.85
Parent proxy report 40 85.10 (13.56) 55.68 100 0.89
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examination, the statistics difference appeared only in
PedsQL™ parent proxy report group (p = 0.01), there is
no significant difference in child self-report parts in both
questionnaires. As shown in Table 3, scores of ever
taking invasive procedures was much higher than others
in PedsQL™ Parent report group. In China, BM examin-
ation is used as necessary diagnosis tools to exclude
other causes of thrombocytopenia. Diagnosed with ITP
may contribute to HRQL of the parents, as a conse-
quence of reduce in concerns about other malignant
diseases may have occurred to their children.
As can be told from Tables 3 and 4, in parent impact
report and child self-report and proxy report group,
PLT, was proportionally correlated with HRQoL scores.
The obvious low scores from parents indicate their
much more concerns on PLT issue. This result
contrasted to the report of Neunert et al. [10]. Although
some guidelines declared patients with absent or minor
bleeding should not be treated regardless of platelet
count, parents were still bothered by the low PLT or the
fear of unpredictable bleeding episodes. Most parents in
China pay much attention to avoid bleeding events, as a
result, much of the daily activities were limited and
might reduce the children’s quality of life. Education,
reassurance and management plan will reduce the worry
and improves quality of life.
Substantial side effects associated with chronic ITP
have been reported recently. The treatment of chronic
ITP in China is in accordance with the American Society
of Hematology 2011 evidence-based practice guideline
for immune thrombocytopenia: 1) Children with no
bleeding or mild bleeding (defined as skin manifestations
only, such as bruising and petechiae) be managed with
observation alone regardless of platelet count. 2) For
pediatric patients requiring treatment, a short course of
corticosteroids or a single dose of IVIG (0.8–1 g/kg for 1
or 2 days, or 0.4 g for 3–5 days) be used as first-line
treatment. 3) A single dose of anti-D can be used as
first-line treatment in Rh-positive, nonsplenectomized
children requiring treatment. 4) High-dose dexametha-
sone may be considered for children or adolescents with
ITP who have significant ongoing bleeding despite treat-
ment with IVIG, anti-D, or conventional doses of corti-
costeroids. 5) Splenectomy or other interventions with
potentially serious complications are the last choices
which should be delayed for at least 12 months [12]. In
subject design phase, we supposed that treatment with
corticosteroids and intravenous immunoglobulin could
improve the HRQoL. We presume that the treatment
would increases platelet count observed in the majority
of patients and provide a concurrent lower risk of bleed-
ing, reducing the fear of bleeding events. This associ-
ation has not been well verified with corticosteroids
here. As with intravenous immunoglobulin, the signifi-
cant difference appeared only in KIT Child self-report
group. For corticosteroids, the adverse effects most often
reported by patients were moon face, weight gain,
personality changes, psychosis, diabetes, cataract and
osteopenia which could decrease HRQoL of patients
[11, 28]. As for intravenous immunoglobulin, the
adverse effects (high donor exposure, risk of transmitted
infection, fever, hemolyis, headache, asceptic meningitis)
and require of intravenous cannula, stay in hospital to get
infusion of immunoglobulin may reduce the overall score.
Table 3 Comparison between scores of child/proxy and parent self-reports in relation to clinical characteristics and treatment of ITP
Clinical Characteristics
and Treatment of ITP
KIT KIT KIT PedsQL™ PedsQL™
Child self-report Parent proxy report Parent impact report Child self-report Parent proxy report
N Mean SD Pa N Mean SD Pa N Mean SD Pa N Mean SD Pa N Mean SD Pa
Gender Male 19 79.29 12.39 0.64 29 72.48 18.92 0.66 29 42.40 17.57 0.29 18 85.40 14.30 0.70 28 85.69 14.25 0.83
Female 5 76.02 13.48 13 75.46 22.78 13 35.92 17.75 4 84.37 12.22 12 82.61 15.37
Platelet count ≤30 8 69.80 14.57 0.01 16 63.45 21.05 0.01 16 34.99 19.35 0.11 8 78.57 14.44 0.14 17 75.44 14.45 0.00
>30 16 83.01 8.63 26 80.17 16.35 26 44.06 15.78 14 88.19 13.36 23 91.53 8.23
BM Never 3 82.51 7.70 0.57 5 65.48 29.57 0.35 5 45.41 20.99 0.51 1 63.04 0.00 - 3 67.06 6.87 0.01
Ever 21 78.05 12.97 37 74.47 18.62 37 39.71 17.39 21 86.18 13.56 37 86.56 12.94
IVIG Neverc 9 84.45 7.00 0.03 17 70.85 17.81 0.50 17 37.05 21.19 0.32 8 86.14 13.94 0.80 16 81.53 11.72 0.17
Everb 15 75.10 13.76 25 75.14 21.48 25 42.66 14.85 14 84.55 14.72 24 87.47 14.41
Corticosteroids Neverc 3 81.22 8.11 0.70 6 63.51 28.86 0.19 6 38.29 28.62 0.85 2 81.52 26.13 0.71 5 82.09 11.73 0.60
Everb 21 78.23 13.00 36 75.05 18.11 36 40.74 15.74 20 85.49 13.53 35 85.52 13.91
Value in bold indicate significant P value
P ≤ 0.05: significant
P ≤ 0.01: highly significant
IVIG, Intravenous immunoglobulin, PLT, Platelet count, BM, Initial bone marrow examination
aTested by ANOVA test
bEver mean ever taking intervention within 4 weeks of questionnaires
cNever mean never taking intervention within 4 weeks of questionnaires
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While balancing pros and cons in intravenous im-
munoglobulin, children obviously consider more of
the disadvantages rather than the benefits. The impact
of adverse effects may counterbalance a potentially
positive effect of corticosteroids on HRQoL scores.
This is partly concordant with the results of Heitink-Polle
et al. and Grainger et al., which showed HRQoL was not
improved by treatment [4, 29].
No significant relation was found between age at onset
or gender with either scores of child/proxy reports or
parent reports. Strullu et al. reported no significant asso-
ciation had been found between sex, age and PedsQL™
scores as well [30]. The effect of splenectomy as a treat-
ment option was not addressed in the study since only 1
respondent had that.
Some limitations of the study should be addressed.
Firstly, the study was limited by the small sample size of
subjects. The age of children should be more than 7 to
finish the child self-report part independently, while the
median age of ITP children here is 5.79 years old, which
severely reduces the number of qualified subjects. It is
essential to validate the results in a larger size of sub-
jects. Secondly, focus was only placed on the traditional
treatment such as IVIG and corticosteroids rather than
some new treatment. Parents in China prefer taking
traditional Chinese medicines concurrently. Many trad-
itional Chinese medicines contain steroid extracts, which
are not taken into discussion in this report. Future
research should take limitations above into account.
ITP is generally a benign disease, while the specificity
of chronic diseases has a strong impact on HRQoL of
patients and their families. The research shows that
HRQoL of ITP children and their parents were influ-
enced by duration of the disease, the PLT, BM and intra-
venous immunoglobulin. Physicians should treat chronic
ITP children with awareness of the families’ anxieties
and closely follow up side effect of invasive procedures
and treatments. KIT can succinctly summarize the
patient and family’s perspective of HRQoL in a more
understandable manner to clinicians. It will be a reliable
outcome measure for further clinical research of HRQoL
of childhood ITP.
Conclusions
ITP affects HRQoL of children and parents. Parents are
much more concerned with the disease than their chil-
dren, which seriously influence their HRQoL as a result.
The cross-culture translated KIT is reliable and valid
with acceptable conrrelation to the PedsQLTM. KIT pro-
vides valuable information of childhood ITP and will be
a reliable outcome measure for further clinical research
on HRQoL.
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